News
NICE recommendation for AbbVie’s Rinvoq
AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has delivered a positive Final Draft Guidance (FDG) recommending its Rinvoq therapy for the treatment of moderately to severely active Crohn’s disease.